What The Peptide Boom Reveals About Modern Leadership

Peptides are more than a health trend. For those in leadership, it reveals something much deeper about power, control, and staying ahead.

BPC-157, TB-500, MOTS-c, and numerous other peptides, once confined to fringe biohackers and athletes, have worked their way into leadership circles. So much so that on July 23rd and 24th, an FDA advisory committee will meet in White Oak, Maryland, to discuss whether a select handful of peptides can be legally produced by compounding pharmacies. According to a recent Bloomberg article, industry investors have put the current black market for these peptides somewhere between $1 and $3 billion.

This surge in peptide use didn't happen in a vacuum. It started with GLP-1s shaping the cultural fabric, as evidenced by the changes Starbucks made to their menu. In fact, Starbucks CEO Brian Niccol has pointed to the company's shift toward a protein-forward menu as a direct response to the eating behaviors he's observed among GLP-1 users.

GLP-1 usage, according to a new Gallup report, has reached an all-time high and is changing the workplace. For leaders, the peptide boom comes down to two things: agency and leverage. Peptides Reflect The Search For Agency In An Uncertain Leadership Environment

The human brain is evolutionarily wired to crave control. Not only is it a survival mechanism, but it also helps us navigate a chaotic world. Leaders, however, operate in anything but a predictable one.

The threat of AI disruption, inflation, geopolitical instability, regulatory shifts, talent shortages, and other business complexities makes an executive's environment increasingly volatile. Most of the variables that determine whether a business survives and grows over the next eighteen months sit outside any one person's hands. In this type of scenario, where few things can bring a sense of control, a leader's biology is one of the few domains where they can still exert direct control.

That pursuit of control carries an undertone of institutional distrust. As crypto emerged as a parallel system when people lost faith in traditional finance, peptides represent a parallel system for people losing faith in traditional healthcare. Peptides fit that instinct precisely.

They promise faster recovery, better sleep, and improved overall performance, all through direct intervention rather than waiting on a system that feels slow and reactive. Whether the science fully supports every claim is a separate question. What matters here is what the interest itself reveals about agency.

Leaders are increasingly treating their biology as a domain of agency, as opposed to fate. When the business environment refuses to hand them control, they go looking for it where they can still find it.